| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 69 | 2024 | 265 | 7.300 |
Why?
|
| Diabetes Mellitus, Type 2 | 69 | 2024 | 1462 | 4.030 |
Why?
|
| Insulin Resistance | 56 | 2022 | 469 | 2.400 |
Why?
|
| Humans | 279 | 2025 | 32779 | 2.060 |
Why?
|
| Female | 204 | 2025 | 20249 | 1.770 |
Why?
|
| Breast Neoplasms | 20 | 2024 | 754 | 1.740 |
Why?
|
| Male | 196 | 2025 | 19624 | 1.640 |
Why?
|
| Cardiovascular Diseases | 34 | 2024 | 1140 | 1.640 |
Why?
|
| Adolescent | 91 | 2024 | 3627 | 1.600 |
Why?
|
| Ventricular Function, Left | 15 | 2024 | 252 | 1.480 |
Why?
|
| Child | 69 | 2024 | 2471 | 1.310 |
Why?
|
| Risk Factors | 72 | 2024 | 3974 | 1.270 |
Why?
|
| Stroke Volume | 14 | 2024 | 370 | 1.250 |
Why?
|
| Middle Aged | 115 | 2025 | 12115 | 1.220 |
Why?
|
| Adult | 99 | 2024 | 9547 | 1.210 |
Why?
|
| Head and Neck Neoplasms | 7 | 2023 | 133 | 1.190 |
Why?
|
| Antineoplastic Agents | 14 | 2020 | 599 | 1.130 |
Why?
|
| Young Adult | 53 | 2024 | 2730 | 1.060 |
Why?
|
| Anthracyclines | 10 | 2020 | 52 | 1.060 |
Why?
|
| Myocardium | 6 | 2023 | 191 | 1.060 |
Why?
|
| Magnetic Resonance Imaging, Cine | 5 | 2023 | 96 | 1.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2024 | 112 | 1.040 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2023 | 157 | 1.030 |
Why?
|
| Arteriosclerosis | 29 | 2005 | 124 | 0.980 |
Why?
|
| Lung Neoplasms | 8 | 2024 | 428 | 0.980 |
Why?
|
| Diabetic Angiopathies | 11 | 2019 | 145 | 0.960 |
Why?
|
| Aged | 74 | 2025 | 10534 | 0.930 |
Why?
|
| Stroke | 5 | 2022 | 609 | 0.920 |
Why?
|
| Brain Neoplasms | 9 | 2024 | 647 | 0.910 |
Why?
|
| Neoplasms | 15 | 2024 | 761 | 0.870 |
Why?
|
| Colorectal Neoplasms | 6 | 2015 | 222 | 0.860 |
Why?
|
| Ventricular Dysfunction, Left | 9 | 2024 | 168 | 0.850 |
Why?
|
| Inflammation | 10 | 2019 | 536 | 0.840 |
Why?
|
| Data Interpretation, Statistical | 3 | 2021 | 114 | 0.830 |
Why?
|
| Doxorubicin | 7 | 2024 | 83 | 0.830 |
Why?
|
| Antibiotics, Antineoplastic | 8 | 2019 | 69 | 0.780 |
Why?
|
| F2-Isoprostanes | 4 | 2017 | 20 | 0.770 |
Why?
|
| Insulin | 26 | 2024 | 367 | 0.760 |
Why?
|
| United States | 47 | 2024 | 4108 | 0.760 |
Why?
|
| Hypertension | 16 | 2024 | 976 | 0.750 |
Why?
|
| Negative-Pressure Wound Therapy | 2 | 2020 | 35 | 0.730 |
Why?
|
| Adenomatous Polyps | 3 | 2012 | 8 | 0.720 |
Why?
|
| Surgical Wound Infection | 2 | 2020 | 98 | 0.700 |
Why?
|
| Gastrostomy | 3 | 2017 | 16 | 0.700 |
Why?
|
| Predictive Value of Tests | 20 | 2025 | 887 | 0.700 |
Why?
|
| Enteral Nutrition | 3 | 2017 | 28 | 0.690 |
Why?
|
| Prospective Studies | 29 | 2024 | 2327 | 0.680 |
Why?
|
| Diabetes Mellitus | 12 | 2022 | 422 | 0.680 |
Why?
|
| Health Services Research | 1 | 2021 | 81 | 0.680 |
Why?
|
| Influenza Vaccines | 5 | 2025 | 83 | 0.680 |
Why?
|
| Prostatic Neoplasms | 10 | 2018 | 476 | 0.650 |
Why?
|
| Prevalence | 25 | 2024 | 1002 | 0.650 |
Why?
|
| Models, Statistical | 5 | 2019 | 180 | 0.640 |
Why?
|
| Retrospective Studies | 27 | 2025 | 3700 | 0.640 |
Why?
|
| Orthomyxoviridae Infections | 5 | 2025 | 22 | 0.630 |
Why?
|
| Body Mass Index | 31 | 2021 | 908 | 0.630 |
Why?
|
| Insulin-Secreting Cells | 4 | 2013 | 53 | 0.610 |
Why?
|
| Postoperative Care | 2 | 2019 | 78 | 0.610 |
Why?
|
| Autoantibodies | 3 | 2022 | 49 | 0.590 |
Why?
|
| Arthroscopy | 3 | 2016 | 249 | 0.580 |
Why?
|
| Logistic Models | 16 | 2018 | 783 | 0.570 |
Why?
|
| C-Peptide | 4 | 2024 | 30 | 0.570 |
Why?
|
| Prognosis | 21 | 2024 | 1544 | 0.560 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2023 | 1307 | 0.550 |
Why?
|
| European Continental Ancestry Group | 28 | 2017 | 1163 | 0.540 |
Why?
|
| Statistics as Topic | 2 | 2017 | 104 | 0.540 |
Why?
|
| Blood Glucose | 21 | 2018 | 494 | 0.540 |
Why?
|
| Animals | 40 | 2025 | 7570 | 0.540 |
Why?
|
| Cohort Studies | 24 | 2023 | 1844 | 0.520 |
Why?
|
| Glucose Tolerance Test | 25 | 2009 | 125 | 0.510 |
Why?
|
| Cross-Sectional Studies | 25 | 2024 | 1572 | 0.510 |
Why?
|
| Heart Failure | 6 | 2022 | 695 | 0.500 |
Why?
|
| Independent Living | 1 | 2017 | 105 | 0.500 |
Why?
|
| Heart Ventricles | 4 | 2018 | 146 | 0.490 |
Why?
|
| Fatty Acids | 3 | 2018 | 99 | 0.490 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2017 | 87 | 0.490 |
Why?
|
| Meta-Analysis as Topic | 1 | 2016 | 46 | 0.490 |
Why?
|
| Residence Characteristics | 3 | 2018 | 197 | 0.490 |
Why?
|
| Treatment Outcome | 20 | 2024 | 3437 | 0.480 |
Why?
|
| Research Design | 3 | 2016 | 331 | 0.480 |
Why?
|
| Anterior Cruciate Ligament | 1 | 2016 | 40 | 0.480 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 133 | 0.470 |
Why?
|
| Mechanoreceptors | 1 | 2016 | 39 | 0.470 |
Why?
|
| Bandages | 3 | 2020 | 33 | 0.470 |
Why?
|
| Dyslipidemias | 4 | 2021 | 54 | 0.460 |
Why?
|
| Pain | 2 | 2014 | 294 | 0.460 |
Why?
|
| Skin Neoplasms | 2 | 2014 | 217 | 0.450 |
Why?
|
| Vegetables | 3 | 2013 | 39 | 0.450 |
Why?
|
| Eosinophils | 1 | 2014 | 29 | 0.440 |
Why?
|
| Fruit | 3 | 2013 | 56 | 0.440 |
Why?
|
| Pruritus | 1 | 2014 | 47 | 0.440 |
Why?
|
| Mice | 22 | 2024 | 2511 | 0.430 |
Why?
|
| Needs Assessment | 1 | 2014 | 75 | 0.430 |
Why?
|
| Cell Line, Tumor | 16 | 2024 | 726 | 0.430 |
Why?
|
| Mutation | 6 | 2024 | 493 | 0.430 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2025 | 21 | 0.430 |
Why?
|
| Time Factors | 21 | 2022 | 2180 | 0.420 |
Why?
|
| Clinical Trials as Topic | 3 | 2012 | 307 | 0.420 |
Why?
|
| Age Factors | 16 | 2021 | 1197 | 0.410 |
Why?
|
| Radiosurgery | 4 | 2022 | 361 | 0.410 |
Why?
|
| Oxidative Stress | 6 | 2024 | 239 | 0.400 |
Why?
|
| Hispanic Americans | 21 | 2017 | 930 | 0.400 |
Why?
|
| Disease Progression | 10 | 2024 | 594 | 0.390 |
Why?
|
| Carotid Arteries | 9 | 2013 | 101 | 0.390 |
Why?
|
| African Continental Ancestry Group | 17 | 2009 | 363 | 0.370 |
Why?
|
| Prostatic Hyperplasia | 3 | 2018 | 44 | 0.360 |
Why?
|
| Poverty | 5 | 2024 | 116 | 0.360 |
Why?
|
| Food Supply | 3 | 2018 | 67 | 0.360 |
Why?
|
| Colonic Polyps | 1 | 2011 | 14 | 0.360 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2011 | 20 | 0.360 |
Why?
|
| Hyperglycemia | 6 | 2018 | 81 | 0.360 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2021 | 531 | 0.360 |
Why?
|
| Neoplasm Metastasis | 4 | 2021 | 220 | 0.350 |
Why?
|
| Antibodies, Viral | 5 | 2025 | 65 | 0.350 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 83 | 0.350 |
Why?
|
| Calcium | 3 | 2019 | 323 | 0.340 |
Why?
|
| Sexual Dysfunctions, Psychological | 2 | 2001 | 7 | 0.340 |
Why?
|
| Heart Rate | 8 | 2022 | 343 | 0.340 |
Why?
|
| Lipids | 7 | 2018 | 229 | 0.330 |
Why?
|
| Incidence | 13 | 2023 | 1238 | 0.330 |
Why?
|
| Diabetes Complications | 5 | 2023 | 182 | 0.330 |
Why?
|
| Obesity | 14 | 2020 | 1152 | 0.330 |
Why?
|
| Aged, 80 and over | 11 | 2024 | 4032 | 0.330 |
Why?
|
| Topography, Medical | 1 | 2010 | 2 | 0.320 |
Why?
|
| Lung | 3 | 2025 | 265 | 0.320 |
Why?
|
| Nutrition Surveys | 5 | 2024 | 150 | 0.320 |
Why?
|
| Vaccines, Inactivated | 4 | 2017 | 39 | 0.320 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 456 | 0.320 |
Why?
|
| Longitudinal Studies | 9 | 2023 | 779 | 0.310 |
Why?
|
| Atherosclerosis | 8 | 2015 | 788 | 0.310 |
Why?
|
| Intention to Treat Analysis | 2 | 2021 | 28 | 0.310 |
Why?
|
| Sarcoma | 2 | 2020 | 71 | 0.310 |
Why?
|
| Magnetic Field Therapy | 2 | 2019 | 17 | 0.300 |
Why?
|
| Adjuvants, Immunologic | 4 | 2018 | 54 | 0.300 |
Why?
|
| Colonoscopy | 5 | 2014 | 45 | 0.300 |
Why?
|
| Triglycerides | 15 | 2021 | 228 | 0.300 |
Why?
|
| Calcium Channels, T-Type | 2 | 2019 | 29 | 0.300 |
Why?
|
| Adenoma | 3 | 2015 | 35 | 0.300 |
Why?
|
| Hypertrophy, Left Ventricular | 3 | 2019 | 121 | 0.300 |
Why?
|
| Case-Control Studies | 14 | 2022 | 876 | 0.290 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 4 | 2011 | 54 | 0.290 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2024 | 146 | 0.290 |
Why?
|
| Brain | 4 | 2022 | 946 | 0.280 |
Why?
|
| Child, Preschool | 16 | 2019 | 1276 | 0.280 |
Why?
|
| Diabetic Retinopathy | 2 | 2023 | 73 | 0.280 |
Why?
|
| Diabetic Ketoacidosis | 2 | 2021 | 12 | 0.280 |
Why?
|
| Cardiotoxins | 2 | 2018 | 8 | 0.280 |
Why?
|
| Odds Ratio | 11 | 2018 | 467 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2020 | 384 | 0.280 |
Why?
|
| Follow-Up Studies | 17 | 2020 | 2282 | 0.280 |
Why?
|
| Body Size | 2 | 2009 | 34 | 0.280 |
Why?
|
| Data Mining | 2 | 2018 | 13 | 0.280 |
Why?
|
| Contrast Media | 2 | 2025 | 138 | 0.270 |
Why?
|
| Cyclophosphamide | 2 | 2024 | 41 | 0.270 |
Why?
|
| Flagellin | 3 | 2016 | 16 | 0.270 |
Why?
|
| Ischemic Attack, Transient | 2 | 2018 | 48 | 0.270 |
Why?
|
| Blood Pressure | 9 | 2017 | 861 | 0.270 |
Why?
|
| Pharmacoepidemiology | 1 | 2007 | 2 | 0.270 |
Why?
|
| Cluster Analysis | 5 | 2021 | 126 | 0.270 |
Why?
|
| Glucose Intolerance | 10 | 2009 | 46 | 0.260 |
Why?
|
| Fasting | 11 | 2013 | 94 | 0.260 |
Why?
|
| Cell Proliferation | 10 | 2020 | 602 | 0.260 |
Why?
|
| Glioblastoma | 2 | 2020 | 157 | 0.260 |
Why?
|
| Albuminuria | 3 | 2017 | 180 | 0.260 |
Why?
|
| Quality of Life | 7 | 2024 | 961 | 0.250 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2025 | 50 | 0.250 |
Why?
|
| Immunotherapy | 4 | 2024 | 94 | 0.250 |
Why?
|
| Fibrinogen | 9 | 2019 | 45 | 0.250 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 8 | 2003 | 43 | 0.250 |
Why?
|
| Patient Compliance | 4 | 2014 | 218 | 0.250 |
Why?
|
| Ethnic Groups | 17 | 2015 | 474 | 0.250 |
Why?
|
| Prostate | 4 | 2016 | 69 | 0.240 |
Why?
|
| African Americans | 16 | 2017 | 1424 | 0.240 |
Why?
|
| Age of Onset | 7 | 2018 | 92 | 0.240 |
Why?
|
| Femoral Artery | 2 | 2018 | 50 | 0.240 |
Why?
|
| Nanotubes, Carbon | 3 | 2011 | 23 | 0.240 |
Why?
|
| Ultrasonography | 5 | 2023 | 378 | 0.240 |
Why?
|
| Environmental Exposure | 2 | 2019 | 89 | 0.240 |
Why?
|
| Piperazines | 4 | 2011 | 52 | 0.230 |
Why?
|
| C-Reactive Protein | 9 | 2019 | 237 | 0.230 |
Why?
|
| Cholesterol, LDL | 8 | 2021 | 171 | 0.230 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2025 | 8 | 0.230 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 193 | 0.230 |
Why?
|
| Heart | 3 | 2023 | 185 | 0.230 |
Why?
|
| Adiposity | 2 | 2018 | 198 | 0.230 |
Why?
|
| Adipose Tissue | 8 | 2009 | 349 | 0.230 |
Why?
|
| Receptor, trkA | 1 | 2024 | 2 | 0.230 |
Why?
|
| Diabetic Neuropathies | 3 | 2023 | 26 | 0.230 |
Why?
|
| Mice, Nude | 8 | 2020 | 290 | 0.230 |
Why?
|
| Risk Assessment | 10 | 2025 | 1460 | 0.230 |
Why?
|
| Radiation Oncology | 1 | 2024 | 12 | 0.220 |
Why?
|
| Hematologic Neoplasms | 2 | 2015 | 34 | 0.220 |
Why?
|
| Narcolepsy | 1 | 2024 | 1 | 0.220 |
Why?
|
| Sodium Oxybate | 1 | 2024 | 2 | 0.220 |
Why?
|
| Vincristine | 1 | 2024 | 20 | 0.220 |
Why?
|
| Cytokines | 3 | 2018 | 247 | 0.220 |
Why?
|
| Etoposide | 1 | 2024 | 36 | 0.220 |
Why?
|
| Melanoma | 3 | 2019 | 165 | 0.220 |
Why?
|
| Prednisone | 1 | 2024 | 62 | 0.220 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 16 | 0.220 |
Why?
|
| Nanoparticles | 1 | 2025 | 56 | 0.220 |
Why?
|
| Neoplasm Staging | 4 | 2023 | 470 | 0.220 |
Why?
|
| Vesicular stomatitis Indiana virus | 2 | 2015 | 13 | 0.210 |
Why?
|
| Membrane Glycoproteins | 2 | 2018 | 98 | 0.210 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2024 | 95 | 0.210 |
Why?
|
| Air Pollutants | 2 | 2019 | 23 | 0.210 |
Why?
|
| Sulfones | 2 | 2020 | 20 | 0.210 |
Why?
|
| Oncolytic Virotherapy | 2 | 2015 | 16 | 0.210 |
Why?
|
| Vitamin D | 2 | 2017 | 189 | 0.210 |
Why?
|
| Income | 1 | 2024 | 67 | 0.210 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2014 | 26 | 0.210 |
Why?
|
| Diet | 5 | 2011 | 390 | 0.210 |
Why?
|
| Colorado | 9 | 2015 | 42 | 0.210 |
Why?
|
| Multivariate Analysis | 11 | 2017 | 682 | 0.200 |
Why?
|
| Hypnotics and Sedatives | 4 | 2011 | 29 | 0.200 |
Why?
|
| Cardiovascular System | 1 | 2023 | 46 | 0.200 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2024 | 97 | 0.200 |
Why?
|
| Laryngeal Neoplasms | 1 | 2023 | 16 | 0.200 |
Why?
|
| Mouth Neoplasms | 1 | 2023 | 19 | 0.200 |
Why?
|
| Health Behavior | 4 | 2013 | 234 | 0.200 |
Why?
|
| Infant | 11 | 2019 | 1081 | 0.200 |
Why?
|
| Tonsillar Neoplasms | 1 | 2023 | 5 | 0.200 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2023 | 35 | 0.200 |
Why?
|
| Retinal Diseases | 1 | 2023 | 25 | 0.200 |
Why?
|
| Gene Expression Profiling | 5 | 2019 | 316 | 0.200 |
Why?
|
| Health Personnel | 2 | 2014 | 130 | 0.190 |
Why?
|
| Nervous System Diseases | 1 | 2023 | 41 | 0.190 |
Why?
|
| Azabicyclo Compounds | 3 | 2011 | 7 | 0.190 |
Why?
|
| Carotid Artery Diseases | 3 | 2000 | 116 | 0.190 |
Why?
|
| Papillomavirus Infections | 1 | 2023 | 68 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2025 | 947 | 0.190 |
Why?
|
| Sex Factors | 11 | 2017 | 675 | 0.190 |
Why?
|
| Television | 2 | 2014 | 13 | 0.190 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2024 | 203 | 0.190 |
Why?
|
| Waist Circumference | 5 | 2018 | 92 | 0.190 |
Why?
|
| Dietary Fiber | 3 | 2014 | 20 | 0.190 |
Why?
|
| Iron | 3 | 2013 | 116 | 0.190 |
Why?
|
| Vaccination | 3 | 2025 | 146 | 0.190 |
Why?
|
| Survivors | 3 | 2022 | 168 | 0.180 |
Why?
|
| Algorithms | 3 | 2024 | 511 | 0.180 |
Why?
|
| Staphylococcal Infections | 4 | 2005 | 78 | 0.180 |
Why?
|
| Neoadjuvant Therapy | 2 | 2019 | 66 | 0.180 |
Why?
|
| Health Education | 2 | 2013 | 162 | 0.180 |
Why?
|
| Reproducibility of Results | 5 | 2014 | 767 | 0.180 |
Why?
|
| Patient Discharge | 3 | 2018 | 204 | 0.180 |
Why?
|
| Aromatase Inhibitors | 1 | 2021 | 9 | 0.180 |
Why?
|
| Animals, Newborn | 5 | 2025 | 119 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2024 | 205 | 0.180 |
Why?
|
| Lipoproteins | 4 | 2008 | 86 | 0.180 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2018 | 23 | 0.180 |
Why?
|
| Microcirculation | 1 | 2021 | 64 | 0.180 |
Why?
|
| Premenopause | 1 | 2021 | 44 | 0.170 |
Why?
|
| Receptor, EphA2 | 1 | 2021 | 13 | 0.170 |
Why?
|
| Ovary | 1 | 2021 | 58 | 0.170 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2018 | 175 | 0.170 |
Why?
|
| Pilot Projects | 4 | 2021 | 565 | 0.170 |
Why?
|
| Models, Biological | 3 | 2019 | 391 | 0.170 |
Why?
|
| Collagen | 2 | 2019 | 219 | 0.170 |
Why?
|
| NAD | 2 | 2018 | 27 | 0.170 |
Why?
|
| Citric Acid Cycle | 1 | 2020 | 11 | 0.170 |
Why?
|
| Disease Models, Animal | 8 | 2019 | 1012 | 0.170 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2020 | 18 | 0.170 |
Why?
|
| Pesticides | 2 | 2013 | 196 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 264 | 0.170 |
Why?
|
| Extremities | 1 | 2020 | 54 | 0.170 |
Why?
|
| Diabetes, Gestational | 2 | 2013 | 27 | 0.160 |
Why?
|
| Linear Models | 11 | 2014 | 445 | 0.160 |
Why?
|
| Indans | 1 | 2020 | 34 | 0.160 |
Why?
|
| Neutrophils | 1 | 2021 | 110 | 0.160 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2020 | 37 | 0.160 |
Why?
|
| Microglia | 2 | 2018 | 68 | 0.160 |
Why?
|
| Ohio | 6 | 2015 | 64 | 0.160 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 44 | 0.160 |
Why?
|
| Ventricular Remodeling | 2 | 2019 | 64 | 0.160 |
Why?
|
| Groin | 1 | 2020 | 6 | 0.160 |
Why?
|
| Primates | 2 | 2017 | 116 | 0.160 |
Why?
|
| Adenocarcinoma | 2 | 2017 | 300 | 0.160 |
Why?
|
| Depressive Disorder, Major | 2 | 2010 | 41 | 0.160 |
Why?
|
| Granulation Tissue | 1 | 2019 | 2 | 0.160 |
Why?
|
| Cognition Disorders | 2 | 2014 | 370 | 0.160 |
Why?
|
| Antibody Formation | 2 | 2017 | 47 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2024 | 115 | 0.160 |
Why?
|
| Glioma | 1 | 2021 | 136 | 0.160 |
Why?
|
| Vehicle Emissions | 1 | 2019 | 3 | 0.160 |
Why?
|
| Program Evaluation | 4 | 2013 | 181 | 0.160 |
Why?
|
| Drug Delivery Systems | 2 | 2021 | 105 | 0.150 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2019 | 18 | 0.150 |
Why?
|
| Edema, Cardiac | 2 | 2016 | 11 | 0.150 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 80 | 0.150 |
Why?
|
| Likelihood Functions | 1 | 1999 | 48 | 0.150 |
Why?
|
| Staphylococcus aureus | 4 | 2005 | 54 | 0.150 |
Why?
|
| Outpatients | 2 | 2018 | 57 | 0.150 |
Why?
|
| Vascular Surgical Procedures | 1 | 2020 | 91 | 0.150 |
Why?
|
| Cholesterol, HDL | 9 | 2021 | 175 | 0.150 |
Why?
|
| Fibrosis | 5 | 2019 | 122 | 0.150 |
Why?
|
| North Carolina | 7 | 2018 | 1546 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 61 | 0.150 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2019 | 43 | 0.150 |
Why?
|
| Postoperative Complications | 2 | 2015 | 828 | 0.150 |
Why?
|
| Muscle Proteins | 1 | 2019 | 63 | 0.150 |
Why?
|
| Urinary Bladder | 2 | 2012 | 183 | 0.150 |
Why?
|
| Socioeconomic Factors | 6 | 2018 | 436 | 0.150 |
Why?
|
| Muscular Atrophy | 1 | 2019 | 76 | 0.140 |
Why?
|
| Nicotine | 1 | 2021 | 177 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2022 | 835 | 0.140 |
Why?
|
| Pertussis Vaccine | 1 | 2018 | 2 | 0.140 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 391 | 0.140 |
Why?
|
| Depression | 1 | 2022 | 448 | 0.140 |
Why?
|
| Vitamin B 12 | 1 | 2018 | 7 | 0.140 |
Why?
|
| Bordetella pertussis | 1 | 2018 | 7 | 0.140 |
Why?
|
| Atherectomy | 1 | 2018 | 4 | 0.140 |
Why?
|
| Feasibility Studies | 3 | 2017 | 308 | 0.140 |
Why?
|
| Popliteal Artery | 1 | 2018 | 6 | 0.140 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 102 | 0.140 |
Why?
|
| Stress, Physiological | 2 | 2020 | 54 | 0.140 |
Why?
|
| Cholesterol | 3 | 2012 | 253 | 0.140 |
Why?
|
| Whooping Cough | 1 | 2018 | 11 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 19 | 0.140 |
Why?
|
| Wound Healing | 1 | 2019 | 188 | 0.140 |
Why?
|
| Microfilament Proteins | 1 | 2018 | 34 | 0.140 |
Why?
|
| Infant, Newborn | 7 | 2016 | 694 | 0.140 |
Why?
|
| Adiponectin | 2 | 2009 | 103 | 0.140 |
Why?
|
| Angioplasty | 1 | 2018 | 34 | 0.140 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 48 | 0.140 |
Why?
|
| Vascular Patency | 1 | 2018 | 69 | 0.140 |
Why?
|
| Survival Rate | 5 | 2020 | 894 | 0.140 |
Why?
|
| Interferon-beta | 2 | 2015 | 18 | 0.140 |
Why?
|
| Abdominal Pain | 2 | 2017 | 43 | 0.140 |
Why?
|
| Dexamethasone | 1 | 2018 | 47 | 0.140 |
Why?
|
| Cisplatin | 1 | 2018 | 81 | 0.140 |
Why?
|
| Patient Readmission | 2 | 2017 | 134 | 0.140 |
Why?
|
| Community Health Services | 2 | 2013 | 58 | 0.140 |
Why?
|
| Exosomes | 1 | 2018 | 44 | 0.140 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 154 | 0.140 |
Why?
|
| Cost Savings | 1 | 2017 | 35 | 0.140 |
Why?
|
| Patient-Centered Care | 1 | 2018 | 72 | 0.140 |
Why?
|
| Orthomyxoviridae | 1 | 2017 | 15 | 0.140 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2015 | 60 | 0.140 |
Why?
|
| Cystatin C | 1 | 2017 | 32 | 0.130 |
Why?
|
| Proinsulin | 4 | 2002 | 11 | 0.130 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 100 | 0.130 |
Why?
|
| Cardiac Volume | 1 | 2017 | 13 | 0.130 |
Why?
|
| Hematologic Diseases | 1 | 2017 | 23 | 0.130 |
Why?
|
| Medicare | 1 | 2018 | 213 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 22 | 0.130 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 2 | 2018 | 13 | 0.130 |
Why?
|
| Hypothermia, Induced | 1 | 2017 | 16 | 0.130 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 54 | 0.130 |
Why?
|
| Ferritins | 2 | 2025 | 48 | 0.130 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 245 | 0.130 |
Why?
|
| Propanolamines | 2 | 2013 | 11 | 0.130 |
Why?
|
| Bone Neoplasms | 1 | 2018 | 116 | 0.130 |
Why?
|
| bcl-Associated Death Protein | 3 | 2013 | 8 | 0.130 |
Why?
|
| Smoking | 9 | 2021 | 531 | 0.130 |
Why?
|
| Oxidation-Reduction | 2 | 2015 | 267 | 0.130 |
Why?
|
| Pepsin A | 1 | 2016 | 4 | 0.130 |
Why?
|
| Ephrin-A5 | 1 | 2016 | 2 | 0.130 |
Why?
|
| Oropharynx | 1 | 2016 | 8 | 0.130 |
Why?
|
| Esophageal pH Monitoring | 1 | 2016 | 3 | 0.130 |
Why?
|
| Scalp | 1 | 2017 | 36 | 0.130 |
Why?
|
| Caregivers | 2 | 2017 | 121 | 0.130 |
Why?
|
| Immunotoxins | 1 | 2016 | 17 | 0.130 |
Why?
|
| Electric Impedance | 1 | 2016 | 13 | 0.130 |
Why?
|
| Body Constitution | 7 | 2005 | 25 | 0.130 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2016 | 18 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2013 | 63 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2018 | 182 | 0.130 |
Why?
|
| Patient Admission | 1 | 2017 | 59 | 0.130 |
Why?
|
| Fluoxetine | 3 | 2011 | 16 | 0.130 |
Why?
|
| Epinephrine | 2 | 2013 | 40 | 0.130 |
Why?
|
| Alopecia | 1 | 2017 | 29 | 0.130 |
Why?
|
| Antidepressive Agents, Second-Generation | 3 | 2011 | 11 | 0.130 |
Why?
|
| Parents | 2 | 2015 | 148 | 0.130 |
Why?
|
| Hospice Care | 1 | 2016 | 13 | 0.130 |
Why?
|
| Health Care Costs | 1 | 2017 | 122 | 0.130 |
Why?
|
| Saliva | 1 | 2016 | 39 | 0.130 |
Why?
|
| Terminal Care | 1 | 2016 | 25 | 0.120 |
Why?
|
| Gastroesophageal Reflux | 1 | 2016 | 20 | 0.120 |
Why?
|
| Autonomic Nervous System | 2 | 2013 | 44 | 0.120 |
Why?
|
| Ethylenediamines | 1 | 2016 | 6 | 0.120 |
Why?
|
| Chelating Agents | 1 | 2016 | 17 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 4 | 2020 | 169 | 0.120 |
Why?
|
| Risk | 3 | 2018 | 315 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2018 | 188 | 0.120 |
Why?
|
| Imidazoles | 1 | 2016 | 92 | 0.120 |
Why?
|
| Self Care | 2 | 2014 | 144 | 0.120 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2016 | 27 | 0.120 |
Why?
|
| Zinc | 1 | 2016 | 31 | 0.120 |
Why?
|
| Palliative Care | 1 | 2016 | 51 | 0.120 |
Why?
|
| Islets of Langerhans | 3 | 2006 | 76 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 129 | 0.120 |
Why?
|
| Rural Population | 1 | 2018 | 286 | 0.120 |
Why?
|
| Cardiomyopathies | 1 | 2016 | 66 | 0.120 |
Why?
|
| Glycemic Index | 2 | 2005 | 14 | 0.120 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2015 | 10 | 0.120 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2016 | 50 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2017 | 369 | 0.120 |
Why?
|
| Bilirubin | 1 | 2015 | 25 | 0.120 |
Why?
|
| Polyendocrinopathies, Autoimmune | 1 | 2015 | 1 | 0.120 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2015 | 3 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2017 | 171 | 0.120 |
Why?
|
| Child of Impaired Parents | 1 | 2015 | 3 | 0.110 |
Why?
|
| Carnitine | 1 | 2015 | 14 | 0.110 |
Why?
|
| Health Promotion | 3 | 2014 | 255 | 0.110 |
Why?
|
| Interferon-alpha | 1 | 2015 | 70 | 0.110 |
Why?
|
| Immunoglobulin G | 3 | 2025 | 128 | 0.110 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 94 | 0.110 |
Why?
|
| Simvastatin | 1 | 2014 | 24 | 0.110 |
Why?
|
| Family Health | 1 | 2015 | 78 | 0.110 |
Why?
|
| Tubulin Modulators | 1 | 2014 | 9 | 0.110 |
Why?
|
| Cesium Radioisotopes | 1 | 2014 | 5 | 0.110 |
Why?
|
| Heptanoic Acids | 1 | 2014 | 26 | 0.110 |
Why?
|
| Cosmic Radiation | 1 | 2014 | 14 | 0.110 |
Why?
|
| Air Microbiology | 2 | 2005 | 19 | 0.110 |
Why?
|
| Professional-Family Relations | 1 | 2014 | 14 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 413 | 0.110 |
Why?
|
| Mineralocorticoids | 1 | 2014 | 5 | 0.110 |
Why?
|
| Fludrocortisone | 1 | 2014 | 6 | 0.110 |
Why?
|
| Stomach Diseases | 1 | 2014 | 7 | 0.110 |
Why?
|
| Vasculitis | 1 | 2014 | 24 | 0.110 |
Why?
|
| Computers | 1 | 2014 | 22 | 0.110 |
Why?
|
| Postural Orthostatic Tachycardia Syndrome | 1 | 2014 | 9 | 0.110 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 102 | 0.110 |
Why?
|
| Appendiceal Neoplasms | 1 | 2015 | 98 | 0.110 |
Why?
|
| Serial Publications | 1 | 2014 | 3 | 0.110 |
Why?
|
| Pyrroles | 1 | 2014 | 52 | 0.110 |
Why?
|
| Carbonated Beverages | 2 | 2011 | 5 | 0.110 |
Why?
|
| Microvessels | 1 | 2014 | 28 | 0.110 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2014 | 35 | 0.110 |
Why?
|
| Nausea | 1 | 2014 | 52 | 0.110 |
Why?
|
| Liver | 3 | 2008 | 492 | 0.110 |
Why?
|
| Editorial Policies | 1 | 2014 | 14 | 0.110 |
Why?
|
| Menisci, Tibial | 1 | 2014 | 23 | 0.110 |
Why?
|
| Apolipoproteins B | 2 | 2004 | 46 | 0.110 |
Why?
|
| Nurse Practitioners | 1 | 2014 | 11 | 0.110 |
Why?
|
| Professional Role | 1 | 2014 | 19 | 0.110 |
Why?
|
| Prejudice | 1 | 2014 | 49 | 0.110 |
Why?
|
| Endothelial Cells | 2 | 2013 | 197 | 0.110 |
Why?
|
| Iron Regulatory Protein 2 | 1 | 2013 | 2 | 0.110 |
Why?
|
| Orchiectomy | 1 | 2013 | 12 | 0.100 |
Why?
|
| Health Services Accessibility | 2 | 2013 | 252 | 0.100 |
Why?
|
| Oxygen | 1 | 2014 | 144 | 0.100 |
Why?
|
| Androgens | 1 | 2013 | 28 | 0.100 |
Why?
|
| Crops, Agricultural | 1 | 2013 | 1 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 3 | 2019 | 98 | 0.100 |
Why?
|
| Hot Temperature | 2 | 2014 | 77 | 0.100 |
Why?
|
| DNA, Single-Stranded | 1 | 2013 | 13 | 0.100 |
Why?
|
| Nutrition Therapy | 1 | 2013 | 4 | 0.100 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2013 | 18 | 0.100 |
Why?
|
| Hippocampus | 2 | 2014 | 171 | 0.100 |
Why?
|
| Behavior Control | 1 | 2013 | 3 | 0.100 |
Why?
|
| Coronary Disease | 4 | 2004 | 214 | 0.100 |
Why?
|
| Nanomedicine | 2 | 2013 | 16 | 0.100 |
Why?
|
| Porphyrins | 1 | 2013 | 29 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2024 | 764 | 0.100 |
Why?
|
| Endothelium, Vascular | 1 | 2014 | 155 | 0.100 |
Why?
|
| Preventive Health Services | 1 | 2013 | 44 | 0.100 |
Why?
|
| Physician Assistants | 1 | 2014 | 38 | 0.100 |
Why?
|
| Adolescent Behavior | 1 | 2014 | 63 | 0.100 |
Why?
|
| Autoimmunity | 1 | 2013 | 34 | 0.100 |
Why?
|
| Up-Regulation | 3 | 2019 | 191 | 0.100 |
Why?
|
| Pain Measurement | 1 | 2014 | 356 | 0.100 |
Why?
|
| Registries | 1 | 2014 | 315 | 0.100 |
Why?
|
| Leukemia | 1 | 2013 | 37 | 0.100 |
Why?
|
| Lymphoma | 1 | 2013 | 33 | 0.100 |
Why?
|
| Endothelium, Corneal | 1 | 2013 | 21 | 0.100 |
Why?
|
| Recurrence | 3 | 2024 | 282 | 0.100 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 549 | 0.100 |
Why?
|
| Severity of Illness Index | 4 | 2024 | 881 | 0.100 |
Why?
|
| Urban Population | 1 | 2013 | 93 | 0.100 |
Why?
|
| Body Weights and Measures | 1 | 2012 | 23 | 0.100 |
Why?
|
| Transients and Migrants | 2 | 2012 | 298 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 240 | 0.100 |
Why?
|
| Analysis of Variance | 5 | 2018 | 459 | 0.100 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 91 | 0.100 |
Why?
|
| Muscle, Smooth | 2 | 2012 | 69 | 0.100 |
Why?
|
| Leptin | 2 | 2010 | 73 | 0.100 |
Why?
|
| Shoulder | 1 | 2012 | 49 | 0.090 |
Why?
|
| Tendon Injuries | 1 | 2012 | 40 | 0.090 |
Why?
|
| Alanine Transaminase | 3 | 2007 | 46 | 0.090 |
Why?
|
| Sphygmomanometers | 1 | 2012 | 1 | 0.090 |
Why?
|
| Lymph Nodes | 2 | 2023 | 114 | 0.090 |
Why?
|
| Apoptosis | 4 | 2016 | 362 | 0.090 |
Why?
|
| Rats | 5 | 2014 | 1606 | 0.090 |
Why?
|
| Mercury | 1 | 2012 | 6 | 0.090 |
Why?
|
| Decision Making | 1 | 2014 | 202 | 0.090 |
Why?
|
| Precancerous Conditions | 1 | 2012 | 25 | 0.090 |
Why?
|
| Lipogenesis | 1 | 2012 | 18 | 0.090 |
Why?
|
| Urethral Obstruction | 1 | 2012 | 4 | 0.090 |
Why?
|
| Rotator Cuff | 1 | 2012 | 74 | 0.090 |
Why?
|
| Organ Transplantation | 1 | 2012 | 66 | 0.090 |
Why?
|
| Polymorphism, Genetic | 2 | 2010 | 183 | 0.090 |
Why?
|
| Coronary Vessels | 1 | 2013 | 164 | 0.090 |
Why?
|
| Motor Activity | 2 | 2014 | 327 | 0.090 |
Why?
|
| Calcium Signaling | 1 | 2012 | 46 | 0.090 |
Why?
|
| Antibodies, Neutralizing | 2 | 2025 | 21 | 0.090 |
Why?
|
| Blood Pressure Determination | 1 | 2012 | 102 | 0.090 |
Why?
|
| Signal Transduction | 4 | 2020 | 686 | 0.090 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2011 | 18 | 0.090 |
Why?
|
| Continental Population Groups | 4 | 2009 | 236 | 0.090 |
Why?
|
| Sleep | 3 | 2011 | 89 | 0.090 |
Why?
|
| Lipoproteins, LDL | 3 | 2000 | 80 | 0.090 |
Why?
|
| Sweetening Agents | 1 | 2011 | 8 | 0.090 |
Why?
|
| Dietary Sucrose | 1 | 2011 | 11 | 0.090 |
Why?
|
| Urethra | 1 | 2012 | 100 | 0.090 |
Why?
|
| Preoperative Care | 2 | 2025 | 122 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2013 | 226 | 0.090 |
Why?
|
| Random Allocation | 3 | 2018 | 229 | 0.090 |
Why?
|
| Length of Stay | 3 | 2017 | 329 | 0.080 |
Why?
|
| Cell Survival | 3 | 2020 | 280 | 0.080 |
Why?
|
| Depressive Disorder | 1 | 2011 | 77 | 0.080 |
Why?
|
| Agriculture | 1 | 2012 | 194 | 0.080 |
Why?
|
| Phosphorylation | 3 | 2020 | 226 | 0.080 |
Why?
|
| Catheters, Indwelling | 2 | 2001 | 44 | 0.080 |
Why?
|
| T-Lymphocytes | 3 | 2016 | 129 | 0.080 |
Why?
|
| Cation Transport Proteins | 1 | 2010 | 24 | 0.080 |
Why?
|
| Carrier State | 3 | 2005 | 23 | 0.080 |
Why?
|
| Radiation Injuries | 1 | 2011 | 78 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2002 | 42 | 0.080 |
Why?
|
| Brain Injuries | 1 | 2011 | 91 | 0.080 |
Why?
|
| Chi-Square Distribution | 3 | 2007 | 292 | 0.080 |
Why?
|
| Body Composition | 4 | 2005 | 388 | 0.080 |
Why?
|
| Small-Area Analysis | 1 | 2010 | 2 | 0.080 |
Why?
|
| Regression Analysis | 8 | 2008 | 288 | 0.080 |
Why?
|
| Membrane Proteins | 2 | 2009 | 251 | 0.080 |
Why?
|
| Chronic Disease | 4 | 2019 | 410 | 0.080 |
Why?
|
| Occupational Exposure | 1 | 2012 | 231 | 0.080 |
Why?
|
| Biopsy | 3 | 2018 | 245 | 0.080 |
Why?
|
| Insurance, Health | 2 | 2023 | 97 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 412 | 0.080 |
Why?
|
| Bayes Theorem | 1 | 2010 | 85 | 0.080 |
Why?
|
| Laser Therapy | 1 | 2009 | 56 | 0.080 |
Why?
|
| Rats, Inbred F344 | 3 | 2014 | 134 | 0.080 |
Why?
|
| Aorta | 1 | 2009 | 127 | 0.080 |
Why?
|
| Kininogen, High-Molecular-Weight | 1 | 2009 | 5 | 0.070 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2008 | 5 | 0.070 |
Why?
|
| Adenosine Triphosphatases | 1 | 2009 | 12 | 0.070 |
Why?
|
| DNA Repair Enzymes | 1 | 2009 | 14 | 0.070 |
Why?
|
| DNA Mismatch Repair | 1 | 2009 | 8 | 0.070 |
Why?
|
| Sexual Behavior, Animal | 1 | 2008 | 8 | 0.070 |
Why?
|
| Dietary Carbohydrates | 2 | 2005 | 23 | 0.070 |
Why?
|
| Phototherapy | 1 | 2009 | 51 | 0.070 |
Why?
|
| Myocytes, Cardiac | 2 | 2019 | 94 | 0.070 |
Why?
|
| Iron Chelating Agents | 1 | 2008 | 7 | 0.070 |
Why?
|
| Curcumin | 1 | 2008 | 7 | 0.070 |
Why?
|
| Indians, North American | 1 | 2009 | 110 | 0.070 |
Why?
|
| Food, Formulated | 1 | 2008 | 12 | 0.070 |
Why?
|
| Iron, Dietary | 1 | 2008 | 13 | 0.070 |
Why?
|
| Aging | 3 | 2011 | 938 | 0.070 |
Why?
|
| Internet | 1 | 2010 | 201 | 0.070 |
Why?
|
| Myocardial Infarction | 2 | 2018 | 483 | 0.070 |
Why?
|
| Salvage Therapy | 2 | 2019 | 134 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 80 | 0.070 |
Why?
|
| Erectile Dysfunction | 1 | 2008 | 50 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2020 | 486 | 0.070 |
Why?
|
| Placebo Effect | 2 | 2011 | 14 | 0.070 |
Why?
|
| Age Distribution | 2 | 2019 | 201 | 0.070 |
Why?
|
| Rhinovirus | 2 | 2005 | 9 | 0.070 |
Why?
|
| Common Cold | 2 | 2005 | 11 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2009 | 142 | 0.070 |
Why?
|
| DNA | 1 | 2009 | 218 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2018 | 134 | 0.070 |
Why?
|
| Propensity Score | 2 | 2019 | 48 | 0.070 |
Why?
|
| Exercise | 3 | 2022 | 679 | 0.070 |
Why?
|
| Nasal Mucosa | 2 | 2005 | 18 | 0.070 |
Why?
|
| Pregnancy | 4 | 2013 | 981 | 0.070 |
Why?
|
| Estrogens | 2 | 2023 | 169 | 0.070 |
Why?
|
| Immunohistochemistry | 3 | 2019 | 497 | 0.070 |
Why?
|
| Gene Expression | 2 | 2019 | 334 | 0.070 |
Why?
|
| Breast Feeding | 1 | 2007 | 47 | 0.070 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2008 | 90 | 0.070 |
Why?
|
| Asthma | 1 | 2009 | 262 | 0.070 |
Why?
|
| Anthropometry | 4 | 2010 | 83 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2009 | 205 | 0.070 |
Why?
|
| Enzyme Activation | 2 | 2020 | 133 | 0.060 |
Why?
|
| Pregnancy Complications | 1 | 2008 | 111 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2023 | 86 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2022 | 563 | 0.060 |
Why?
|
| Hyperthermia, Induced | 1 | 2009 | 241 | 0.060 |
Why?
|
| Hyperinsulinism | 3 | 2003 | 13 | 0.060 |
Why?
|
| Carotenoids | 1 | 2006 | 9 | 0.060 |
Why?
|
| Gadolinium | 1 | 2006 | 20 | 0.060 |
Why?
|
| Injections, Intraperitoneal | 2 | 2019 | 47 | 0.060 |
Why?
|
| Anticarcinogenic Agents | 1 | 2006 | 24 | 0.060 |
Why?
|
| Extracellular Matrix | 2 | 2019 | 243 | 0.060 |
Why?
|
| Mass Screening | 2 | 1999 | 268 | 0.060 |
Why?
|
| Hypoglycemic Agents | 3 | 2010 | 180 | 0.060 |
Why?
|
| South Carolina | 3 | 2012 | 32 | 0.060 |
Why?
|
| Birth Weight | 1 | 2006 | 49 | 0.060 |
Why?
|
| Comorbidity | 3 | 2016 | 573 | 0.060 |
Why?
|
| Lipid Peroxidation | 2 | 2017 | 32 | 0.060 |
Why?
|
| Myocardial Ischemia | 1 | 2006 | 105 | 0.060 |
Why?
|
| Phagocytosis | 1 | 2025 | 17 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2004 | 110 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2019 | 77 | 0.060 |
Why?
|
| Discriminant Analysis | 2 | 2009 | 21 | 0.060 |
Why?
|
| Cell Movement | 2 | 2020 | 171 | 0.060 |
Why?
|
| Indazoles | 1 | 2024 | 2 | 0.060 |
Why?
|
| Peer Review | 1 | 2024 | 8 | 0.060 |
Why?
|
| Peer Review, Health Care | 1 | 2024 | 6 | 0.060 |
Why?
|
| Viral Load | 1 | 2025 | 73 | 0.060 |
Why?
|
| Isosorbide Dinitrate | 1 | 2004 | 1 | 0.060 |
Why?
|
| Lymphatic Metastasis | 2 | 2018 | 169 | 0.060 |
Why?
|
| Nitric Oxide Donors | 1 | 2004 | 8 | 0.060 |
Why?
|
| Hydralazine | 1 | 2004 | 7 | 0.060 |
Why?
|
| Cell Death | 2 | 2016 | 71 | 0.060 |
Why?
|
| Battered Women | 1 | 2004 | 2 | 0.060 |
Why?
|
| Vaginal Smears | 2 | 2002 | 9 | 0.060 |
Why?
|
| Patch Tests | 1 | 2004 | 8 | 0.060 |
Why?
|
| Spouse Abuse | 1 | 2004 | 6 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 326 | 0.060 |
Why?
|
| Allergens | 1 | 2004 | 15 | 0.060 |
Why?
|
| Benzamides | 1 | 2024 | 54 | 0.050 |
Why?
|
| Spouses | 1 | 2004 | 14 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2024 | 55 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2004 | 59 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2024 | 60 | 0.050 |
Why?
|
| Picornaviridae Infections | 1 | 2004 | 4 | 0.050 |
Why?
|
| Interleukin-6 | 2 | 2019 | 240 | 0.050 |
Why?
|
| Aryldialkylphosphatase | 1 | 2024 | 6 | 0.050 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2004 | 14 | 0.050 |
Why?
|
| Arginine | 1 | 2024 | 18 | 0.050 |
Why?
|
| Demography | 1 | 2004 | 110 | 0.050 |
Why?
|
| Staphylococcus | 1 | 2004 | 10 | 0.050 |
Why?
|
| Patient Education as Topic | 2 | 2018 | 265 | 0.050 |
Why?
|
| Drug Therapy, Combination | 3 | 2011 | 289 | 0.050 |
Why?
|
| Genetic Markers | 2 | 2015 | 125 | 0.050 |
Why?
|
| Human papillomavirus 16 | 1 | 2023 | 4 | 0.050 |
Why?
|
| Genomics | 1 | 2024 | 88 | 0.050 |
Why?
|
| Aromatase | 1 | 2023 | 12 | 0.050 |
Why?
|
| Cross Infection | 1 | 2004 | 56 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2023 | 24 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 152 | 0.050 |
Why?
|
| Neoplasm Transplantation | 2 | 2013 | 72 | 0.050 |
Why?
|
| Itraconazole | 1 | 2003 | 6 | 0.050 |
Why?
|
| Onychomycosis | 1 | 2003 | 8 | 0.050 |
Why?
|
| Foot Dermatoses | 1 | 2003 | 9 | 0.050 |
Why?
|
| Receptors, Adrenergic, beta-2 | 2 | 2013 | 23 | 0.050 |
Why?
|
| Glottis | 1 | 2023 | 7 | 0.050 |
Why?
|
| Naphthalenes | 1 | 2003 | 39 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2003 | 41 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2010 | 525 | 0.050 |
Why?
|
| Patient Satisfaction | 2 | 2018 | 239 | 0.050 |
Why?
|
| Palatine Tonsil | 1 | 2023 | 8 | 0.050 |
Why?
|
| Rats, Inbred BN | 2 | 2014 | 32 | 0.050 |
Why?
|
| Tunica Intima | 3 | 1998 | 57 | 0.050 |
Why?
|
| Protein Binding | 2 | 2016 | 200 | 0.050 |
Why?
|
| Prediabetic State | 1 | 2003 | 72 | 0.050 |
Why?
|
| Echoencephalography | 1 | 2022 | 4 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 208 | 0.050 |
Why?
|
| Temporal Bone | 1 | 2022 | 22 | 0.050 |
Why?
|
| Acute-Phase Proteins | 1 | 2002 | 11 | 0.050 |
Why?
|
| Confidence Intervals | 4 | 2007 | 148 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 78 | 0.050 |
Why?
|
| Alcohol Drinking | 2 | 2004 | 256 | 0.050 |
Why?
|
| Creatinine | 3 | 2013 | 198 | 0.050 |
Why?
|
| Desensitization, Immunologic | 1 | 2001 | 3 | 0.050 |
Why?
|
| Nose | 1 | 2001 | 12 | 0.050 |
Why?
|
| Rural Health | 1 | 2002 | 44 | 0.050 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2001 | 8 | 0.050 |
Why?
|
| Sampling Studies | 2 | 1998 | 44 | 0.050 |
Why?
|
| Purines | 1 | 2001 | 21 | 0.040 |
Why?
|
| Silver Sulfadiazine | 1 | 2001 | 4 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2024 | 352 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 3 | 2009 | 76 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2023 | 576 | 0.040 |
Why?
|
| Chlorhexidine | 1 | 2001 | 6 | 0.040 |
Why?
|
| Convection | 1 | 2021 | 8 | 0.040 |
Why?
|
| Adenosine | 1 | 2021 | 59 | 0.040 |
Why?
|
| Cytotoxins | 1 | 2021 | 13 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 109 | 0.040 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2001 | 18 | 0.040 |
Why?
|
| Prosthesis-Related Infections | 1 | 2001 | 26 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2021 | 106 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 271 | 0.040 |
Why?
|
| Neutrophil Infiltration | 1 | 2021 | 12 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2021 | 23 | 0.040 |
Why?
|
| Dogs | 1 | 2021 | 120 | 0.040 |
Why?
|
| Phosphoserine | 1 | 2020 | 8 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2018 | 360 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2011 | 95 | 0.040 |
Why?
|
| Catalytic Domain | 1 | 2020 | 67 | 0.040 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 2 | 2013 | 3 | 0.040 |
Why?
|
| Anxiety | 1 | 2022 | 195 | 0.040 |
Why?
|
| Disease Susceptibility | 2 | 2015 | 58 | 0.040 |
Why?
|
| Long QT Syndrome | 1 | 2000 | 46 | 0.040 |
Why?
|
| Glutamate Decarboxylase | 2 | 2013 | 17 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2013 | 754 | 0.040 |
Why?
|
| Co-Repressor Proteins | 1 | 2020 | 3 | 0.040 |
Why?
|
| Epidemiologic Methods | 2 | 2013 | 24 | 0.040 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2020 | 17 | 0.040 |
Why?
|
| Tunica Media | 2 | 1997 | 28 | 0.040 |
Why?
|
| Cellulose, Oxidized | 1 | 2019 | 3 | 0.040 |
Why?
|
| Cell Size | 1 | 2019 | 36 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 44 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2019 | 29 | 0.040 |
Why?
|
| Silver | 1 | 2019 | 8 | 0.040 |
Why?
|
| Receptor, erbB-2 | 1 | 2020 | 65 | 0.040 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2010 | 14 | 0.040 |
Why?
|
| Carbon | 1 | 2019 | 11 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2020 | 51 | 0.040 |
Why?
|
| Computational Biology | 1 | 2020 | 94 | 0.040 |
Why?
|
| Air Pollution | 1 | 2019 | 17 | 0.040 |
Why?
|
| Particulate Matter | 1 | 2019 | 28 | 0.040 |
Why?
|
| HMGA2 Protein | 1 | 2019 | 13 | 0.040 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2019 | 11 | 0.040 |
Why?
|
| Electromagnetic Fields | 1 | 2019 | 28 | 0.040 |
Why?
|
| Receptor, Insulin | 1 | 1999 | 10 | 0.040 |
Why?
|
| Radiometry | 1 | 2019 | 40 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2019 | 50 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2019 | 80 | 0.040 |
Why?
|
| Sheep | 1 | 2019 | 233 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 65 | 0.040 |
Why?
|
| Cognition | 1 | 2023 | 551 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 185 | 0.040 |
Why?
|
| World Health Organization | 2 | 2012 | 17 | 0.040 |
Why?
|
| Cell Line | 1 | 2020 | 433 | 0.040 |
Why?
|
| Reference Values | 3 | 2006 | 238 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2019 | 113 | 0.040 |
Why?
|
| Rats, Inbred SHR | 1 | 2018 | 31 | 0.040 |
Why?
|
| Acrylamides | 1 | 2018 | 4 | 0.040 |
Why?
|
| Carotid Stenosis | 1 | 1999 | 59 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2018 | 79 | 0.040 |
Why?
|
| Mediastinum | 1 | 2018 | 14 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2018 | 28 | 0.040 |
Why?
|
| Skin | 2 | 2014 | 214 | 0.040 |
Why?
|
| Alum Compounds | 1 | 2018 | 4 | 0.040 |
Why?
|
| Overweight | 2 | 2012 | 263 | 0.040 |
Why?
|
| Tretinoin | 1 | 2018 | 33 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2018 | 16 | 0.040 |
Why?
|
| Lower Body Negative Pressure | 1 | 1998 | 1 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2019 | 138 | 0.040 |
Why?
|
| Electrocardiography | 2 | 2000 | 636 | 0.040 |
Why?
|
| Myocardial Revascularization | 1 | 2018 | 41 | 0.040 |
Why?
|
| Cranial Irradiation | 1 | 2018 | 93 | 0.040 |
Why?
|
| Infusions, Parenteral | 1 | 2018 | 65 | 0.040 |
Why?
|
| Echocardiography | 1 | 2019 | 182 | 0.030 |
Why?
|
| Social Behavior | 1 | 2018 | 64 | 0.030 |
Why?
|
| Transfection | 1 | 2018 | 184 | 0.030 |
Why?
|
| Models, Animal | 1 | 2018 | 171 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2018 | 76 | 0.030 |
Why?
|
| Abdominal Injuries | 1 | 1998 | 31 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2000 | 332 | 0.030 |
Why?
|
| Piperidines | 1 | 2018 | 120 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1998 | 195 | 0.030 |
Why?
|
| Automation | 1 | 2017 | 30 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2018 | 162 | 0.030 |
Why?
|
| Cause of Death | 1 | 2018 | 240 | 0.030 |
Why?
|
| Lymphopenia | 1 | 2017 | 11 | 0.030 |
Why?
|
| Genes, erbB-1 | 1 | 2017 | 14 | 0.030 |
Why?
|
| Leucovorin | 1 | 2017 | 23 | 0.030 |
Why?
|
| Hypokalemia | 1 | 2017 | 14 | 0.030 |
Why?
|
| Clone Cells | 1 | 2017 | 35 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2017 | 17 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2017 | 23 | 0.030 |
Why?
|
| Neutropenia | 1 | 2017 | 27 | 0.030 |
Why?
|
| Genes, ras | 1 | 2017 | 25 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 28 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 622 | 0.030 |
Why?
|
| Sensation Disorders | 1 | 2017 | 19 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 60 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2018 | 80 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2017 | 96 | 0.030 |
Why?
|
| Sulfides | 1 | 2017 | 26 | 0.030 |
Why?
|
| Caprylates | 1 | 2017 | 27 | 0.030 |
Why?
|
| Hypoalbuminemia | 1 | 2017 | 13 | 0.030 |
Why?
|
| Medical Illustration | 1 | 2017 | 5 | 0.030 |
Why?
|
| Camptothecin | 1 | 2017 | 48 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 46 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2017 | 65 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 135 | 0.030 |
Why?
|
| Parity | 1 | 1996 | 19 | 0.030 |
Why?
|
| Anemia | 1 | 2017 | 57 | 0.030 |
Why?
|
| Labor Stage, First | 1 | 1996 | 9 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 194 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2017 | 82 | 0.030 |
Why?
|
| Diastole | 1 | 2017 | 97 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 84 | 0.030 |
Why?
|
| Single-Chain Antibodies | 1 | 2016 | 3 | 0.030 |
Why?
|
| Taxoids | 1 | 2017 | 55 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2016 | 12 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 188 | 0.030 |
Why?
|
| Stents | 1 | 2018 | 174 | 0.030 |
Why?
|
| Monitoring, Ambulatory | 1 | 2016 | 10 | 0.030 |
Why?
|
| Photography | 1 | 2017 | 43 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2016 | 32 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 98 | 0.030 |
Why?
|
| Headache | 1 | 2017 | 75 | 0.030 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2016 | 5 | 0.030 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2016 | 9 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 112 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2018 | 160 | 0.030 |
Why?
|
| Mitochondria | 1 | 2018 | 206 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 160 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 789 | 0.030 |
Why?
|
| Feeding Behavior | 2 | 2009 | 158 | 0.030 |
Why?
|
| Aptamers, Nucleotide | 1 | 2016 | 10 | 0.030 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2016 | 8 | 0.030 |
Why?
|
| Analgesia, Obstetrical | 1 | 1996 | 47 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 145 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2016 | 24 | 0.030 |
Why?
|
| Analgesia, Epidural | 1 | 1996 | 50 | 0.030 |
Why?
|
| Liposomes | 1 | 2016 | 30 | 0.030 |
Why?
|
| Health Status | 1 | 2018 | 402 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2000 | 543 | 0.030 |
Why?
|
| Women's Health | 1 | 1997 | 235 | 0.030 |
Why?
|
| Idarubicin | 1 | 2015 | 7 | 0.030 |
Why?
|
| Daunorubicin | 1 | 2015 | 27 | 0.030 |
Why?
|
| Aortic Valve | 1 | 2016 | 60 | 0.030 |
Why?
|
| Aortic Valve Stenosis | 1 | 2016 | 41 | 0.030 |
Why?
|
| Cesarean Section | 1 | 1996 | 113 | 0.030 |
Why?
|
| Sepsis | 1 | 2017 | 165 | 0.030 |
Why?
|
| Heart Valve Prosthesis | 1 | 2016 | 60 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2015 | 4 | 0.030 |
Why?
|
| Oncolytic Viruses | 1 | 2015 | 8 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2015 | 11 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 2 | 2005 | 28 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2015 | 59 | 0.030 |
Why?
|
| Weight Loss | 1 | 2018 | 457 | 0.030 |
Why?
|
| Ankle Brachial Index | 1 | 2015 | 40 | 0.030 |
Why?
|
| Patient Selection | 1 | 2016 | 281 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2015 | 185 | 0.030 |
Why?
|
| Respiration | 1 | 2014 | 28 | 0.030 |
Why?
|
| Dentate Gyrus | 1 | 2014 | 6 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 26 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 247 | 0.030 |
Why?
|
| Neurogenesis | 1 | 2014 | 16 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 77 | 0.030 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2014 | 32 | 0.030 |
Why?
|
| Space Flight | 1 | 2014 | 23 | 0.030 |
Why?
|
| Tilt-Table Test | 1 | 2014 | 13 | 0.030 |
Why?
|
| Gamma Rays | 1 | 2014 | 25 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2014 | 82 | 0.030 |
Why?
|
| New England | 1 | 2014 | 3 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 2014 | 83 | 0.030 |
Why?
|
| Forearm | 1 | 2014 | 42 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 60 | 0.030 |
Why?
|
| Apoferritins | 1 | 2013 | 4 | 0.030 |
Why?
|
| Receptors, Transferrin | 1 | 2013 | 10 | 0.030 |
Why?
|
| Knee Injuries | 1 | 2014 | 40 | 0.030 |
Why?
|
| Tosyl Compounds | 1 | 2013 | 3 | 0.030 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2013 | 17 | 0.030 |
Why?
|
| Anilides | 1 | 2013 | 11 | 0.030 |
Why?
|
| Nutrition Policy | 1 | 2014 | 35 | 0.030 |
Why?
|
| Phenylthiohydantoin | 1 | 2013 | 8 | 0.030 |
Why?
|
| Nitriles | 1 | 2013 | 23 | 0.030 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2013 | 27 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2013 | 19 | 0.030 |
Why?
|
| Endosomes | 1 | 2013 | 12 | 0.030 |
Why?
|
| Stearic Acids | 1 | 2013 | 6 | 0.030 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2013 | 4 | 0.030 |
Why?
|
| Patient Participation | 1 | 2014 | 87 | 0.030 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2013 | 29 | 0.030 |
Why?
|
| Docosahexaenoic Acids | 1 | 2013 | 20 | 0.030 |
Why?
|
| American Heart Association | 1 | 2014 | 87 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2013 | 101 | 0.030 |
Why?
|
| Photosensitizing Agents | 1 | 2013 | 24 | 0.030 |
Why?
|
| Hospitalization | 1 | 2016 | 488 | 0.030 |
Why?
|
| Perception | 1 | 2014 | 104 | 0.030 |
Why?
|
| Troponin I | 1 | 2013 | 21 | 0.030 |
Why?
|
| Collagenases | 1 | 2013 | 9 | 0.020 |
Why?
|
| Collagen Type IV | 1 | 2013 | 9 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2013 | 96 | 0.020 |
Why?
|
| Communication | 1 | 2014 | 141 | 0.020 |
Why?
|
| Pituitary-Adrenal System | 1 | 2013 | 21 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 20 | 0.020 |
Why?
|
| Fibronectins | 1 | 2013 | 37 | 0.020 |
Why?
|
| Culture Media | 1 | 2013 | 45 | 0.020 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2013 | 31 | 0.020 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2013 | 72 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2013 | 28 | 0.020 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2013 | 57 | 0.020 |
Why?
|
| Program Development | 1 | 2013 | 96 | 0.020 |
Why?
|
| Lipoproteins, HDL | 2 | 2008 | 252 | 0.020 |
Why?
|
| Viral Matrix Proteins | 1 | 2012 | 9 | 0.020 |
Why?
|
| Drug Combinations | 2 | 2004 | 99 | 0.020 |
Why?
|
| Lacerations | 1 | 2012 | 9 | 0.020 |
Why?
|
| Shoulder Impingement Syndrome | 1 | 2012 | 11 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2013 | 78 | 0.020 |
Why?
|
| Brachial Artery | 1 | 2013 | 69 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2013 | 122 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 163 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2012 | 35 | 0.020 |
Why?
|
| Virus Replication | 1 | 2012 | 42 | 0.020 |
Why?
|
| Adenylate Kinase | 1 | 2012 | 3 | 0.020 |
Why?
|
| Tendons | 1 | 2012 | 59 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2012 | 20 | 0.020 |
Why?
|
| Phospholipids | 1 | 2012 | 29 | 0.020 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2012 | 5 | 0.020 |
Why?
|
| Inservice Training | 1 | 2012 | 12 | 0.020 |
Why?
|
| rho-Associated Kinases | 1 | 2012 | 7 | 0.020 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2012 | 10 | 0.020 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 2012 | 7 | 0.020 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2012 | 18 | 0.020 |
Why?
|
| Sirtuins | 1 | 2012 | 21 | 0.020 |
Why?
|
| Urodynamics | 1 | 2012 | 36 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2012 | 31 | 0.020 |
Why?
|
| Publishing | 1 | 2012 | 62 | 0.020 |
Why?
|
| Observer Variation | 1 | 2012 | 96 | 0.020 |
Why?
|
| Minority Groups | 1 | 2012 | 86 | 0.020 |
Why?
|
| Calcium Channels, L-Type | 1 | 2012 | 45 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2013 | 166 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2011 | 9 | 0.020 |
Why?
|
| Community-Based Participatory Research | 1 | 2012 | 120 | 0.020 |
Why?
|
| Weight Gain | 1 | 2012 | 112 | 0.020 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2011 | 23 | 0.020 |
Why?
|
| Insulin Antibodies | 1 | 2011 | 2 | 0.020 |
Why?
|
| von Willebrand Factor | 1 | 2011 | 14 | 0.020 |
Why?
|
| Social Class | 1 | 2012 | 93 | 0.020 |
Why?
|
| Platelet Count | 1 | 2011 | 23 | 0.020 |
Why?
|
| Platelet Activation | 1 | 2011 | 14 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2011 | 43 | 0.020 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2011 | 18 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2012 | 120 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2011 | 94 | 0.020 |
Why?
|
| Tamoxifen | 1 | 2011 | 59 | 0.020 |
Why?
|
| Wakefulness | 1 | 2011 | 26 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 475 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 2011 | 49 | 0.020 |
Why?
|
| Sex Characteristics | 2 | 2004 | 172 | 0.020 |
Why?
|
| Calcium, Dietary | 1 | 2011 | 23 | 0.020 |
Why?
|
| Neurons | 1 | 2014 | 416 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 820 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2013 | 192 | 0.020 |
Why?
|
| Glucose Clamp Technique | 1 | 2010 | 12 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2001 | 80 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2010 | 18 | 0.020 |
Why?
|
| Thrombosis | 1 | 2011 | 80 | 0.020 |
Why?
|
| Rabbits | 2 | 2001 | 192 | 0.020 |
Why?
|
| Metabolic Equivalent | 1 | 2010 | 3 | 0.020 |
Why?
|
| Video Games | 1 | 2010 | 5 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2011 | 109 | 0.020 |
Why?
|
| Puberty | 1 | 2010 | 7 | 0.020 |
Why?
|
| Affect | 1 | 2010 | 70 | 0.020 |
Why?
|
| Breast | 1 | 2010 | 64 | 0.020 |
Why?
|
| Mexico | 2 | 2003 | 72 | 0.020 |
Why?
|
| Solubility | 1 | 2009 | 38 | 0.020 |
Why?
|
| Emigrants and Immigrants | 1 | 2012 | 240 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2010 | 129 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2009 | 100 | 0.020 |
Why?
|
| Infrared Rays | 1 | 2009 | 20 | 0.020 |
Why?
|
| Water | 1 | 2009 | 61 | 0.020 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2009 | 39 | 0.020 |
Why?
|
| Dairy Products | 1 | 2009 | 13 | 0.020 |
Why?
|
| Meat | 1 | 2009 | 16 | 0.020 |
Why?
|
| DNA Primers | 1 | 2009 | 89 | 0.020 |
Why?
|
| Temperature | 1 | 2009 | 51 | 0.020 |
Why?
|
| Particle Size | 2 | 1999 | 47 | 0.020 |
Why?
|
| Physical Fitness | 1 | 2010 | 133 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2009 | 33 | 0.020 |
Why?
|
| Bronchodilator Agents | 1 | 2009 | 49 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 59 | 0.020 |
Why?
|
| Diet, Fat-Restricted | 1 | 2009 | 31 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2010 | 257 | 0.020 |
Why?
|
| Skinfold Thickness | 1 | 2009 | 7 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2009 | 9 | 0.020 |
Why?
|
| Base Sequence | 1 | 2009 | 247 | 0.020 |
Why?
|
| Penile Erection | 1 | 2008 | 21 | 0.020 |
Why?
|
| Asian Continental Ancestry Group | 2 | 1999 | 108 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2008 | 27 | 0.020 |
Why?
|
| Hematocrit | 1 | 2008 | 23 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2008 | 49 | 0.020 |
Why?
|
| Energy Intake | 1 | 2009 | 128 | 0.020 |
Why?
|
| Transferrin | 1 | 2008 | 33 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2009 | 121 | 0.020 |
Why?
|
| Body Weight | 1 | 2010 | 301 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2009 | 128 | 0.020 |
Why?
|
| Life Style | 1 | 2011 | 407 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2009 | 83 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2009 | 114 | 0.020 |
Why?
|
| Spleen | 1 | 2008 | 85 | 0.020 |
Why?
|
| Phenotype | 1 | 2009 | 638 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2008 | 202 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2009 | 453 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2008 | 431 | 0.020 |
Why?
|
| Energy Metabolism | 2 | 1999 | 155 | 0.020 |
Why?
|
| Information Systems | 1 | 2006 | 9 | 0.020 |
Why?
|
| Angina, Unstable | 1 | 2006 | 18 | 0.020 |
Why?
|
| Models, Cardiovascular | 1 | 2006 | 30 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2006 | 63 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2006 | 18 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2006 | 17 | 0.020 |
Why?
|
| Tachycardia, Ventricular | 1 | 2006 | 27 | 0.020 |
Why?
|
| Autoantigens | 1 | 2006 | 16 | 0.020 |
Why?
|
| Death | 1 | 2006 | 53 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2006 | 59 | 0.020 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2005 | 18 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2005 | 33 | 0.010 |
Why?
|
| Diet Records | 1 | 2005 | 32 | 0.010 |
Why?
|
| Forecasting | 1 | 2005 | 143 | 0.010 |
Why?
|
| Atmosphere Exposure Chambers | 1 | 2005 | 3 | 0.010 |
Why?
|
| Waist-Hip Ratio | 1 | 2005 | 35 | 0.010 |
Why?
|
| Abdomen | 1 | 2005 | 46 | 0.010 |
Why?
|
| Glucose | 1 | 2006 | 184 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 2004 | 22 | 0.010 |
Why?
|
| Coagulase | 1 | 2004 | 3 | 0.010 |
Why?
|
| Ribotyping | 1 | 2004 | 3 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 2004 | 18 | 0.010 |
Why?
|
| Protective Clothing | 1 | 2004 | 25 | 0.010 |
Why?
|
| Thrombophilia | 1 | 2003 | 8 | 0.010 |
Why?
|
| Blood Proteins | 1 | 2003 | 17 | 0.010 |
Why?
|
| Arthrodermataceae | 1 | 2003 | 3 | 0.010 |
Why?
|
| Homozygote | 1 | 2003 | 58 | 0.010 |
Why?
|
| Genetics, Population | 1 | 2003 | 31 | 0.010 |
Why?
|
| Universities | 1 | 2004 | 153 | 0.010 |
Why?
|
| Heterozygote | 1 | 2003 | 61 | 0.010 |
Why?
|
| Sleep Stages | 1 | 2003 | 6 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2003 | 220 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2003 | 92 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2003 | 99 | 0.010 |
Why?
|
| Students | 1 | 2004 | 179 | 0.010 |
Why?
|
| ROC Curve | 1 | 2003 | 168 | 0.010 |
Why?
|
| Genotype | 1 | 2003 | 731 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2002 | 272 | 0.010 |
Why?
|
| Nephritis | 1 | 2000 | 15 | 0.010 |
Why?
|
| Hypertension, Renal | 1 | 2000 | 29 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2000 | 48 | 0.010 |
Why?
|
| Lipoproteins, VLDL | 1 | 2000 | 27 | 0.010 |
Why?
|
| Dermatitis, Atopic | 1 | 2001 | 102 | 0.010 |
Why?
|
| England | 1 | 1999 | 4 | 0.010 |
Why?
|
| Bacteremia | 1 | 2000 | 65 | 0.010 |
Why?
|
| Cholesterol, VLDL | 1 | 1999 | 11 | 0.010 |
Why?
|
| Fibrinolysis | 1 | 1999 | 7 | 0.010 |
Why?
|
| Mammography | 1 | 1999 | 40 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 1999 | 56 | 0.010 |
Why?
|
| Organ Size | 1 | 1999 | 219 | 0.010 |
Why?
|
| Lung Compliance | 1 | 1998 | 8 | 0.010 |
Why?
|
| Pulmonary Circulation | 1 | 1998 | 4 | 0.010 |
Why?
|
| Viscera | 1 | 1998 | 17 | 0.010 |
Why?
|
| Resuscitation | 1 | 1998 | 67 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1998 | 162 | 0.010 |
Why?
|
| Texas | 1 | 1996 | 40 | 0.010 |
Why?
|
| California | 1 | 1996 | 66 | 0.010 |
Why?
|
| Postmenopause | 1 | 1998 | 427 | 0.010 |
Why?
|
| Africa | 1 | 1996 | 28 | 0.010 |
Why?
|